Jeffrey Edwards, PhD, brings to Anavex 18 years of experience in various aspects of drug development, including DMPK (drug metabolism and pharmacokinetics), Clinical Pharmacology, and Clinical Science. He has been involved in the development and regulatory approval of multiple new chemical entities, among them MYALEPT® (metreleptin), OCALIVA® (obeticholic acid), OLPRUVA® (sodium phenylbutyrate), REZDIFFRA® (resmetirom), and VELSIPITY® (etrasimod). Before joining Anavex, Dr. Edwards served as Vice President of Clinical Science at Acer Therapeutics and positions of increasing responsibility at Madrigal Pharmaceuticals, Intercept Pharmaceuticals, Amylin Pharmaceuticals, and Arena Pharmaceuticals. He received his BS degree in Chemistry from James Madison University, a PhD in Toxicology from the University of Kentucky, and a Post-Doctoral Fellowship at North Carolina State University.